Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical utility of diagnosing lynch syndrome in gynecologic oncology: a joint statement from four japanese academic societies.

International journal of clinical oncology·2026
Same author

AI-Based Analysis of Tumor-Infiltrating Lymphocytes and Homologous Recombination in Ovarian Cancer: JGOG3025-A1 Study.

Cancer science·2026
Same author

A case of cystic hygroma with confined placental mosaicism of tetraploidy leading to noonan syndrome.

Taiwanese journal of obstetrics & gynecology·2026
Same author

Nationwide survey of hereditary breast and ovarian cancer-related clinical practice in gynecologic oncology in Japan: a joint study by the Japan Society of Gynecologic Oncology (JSGO) and the Japan Society of Obstetrics and Gynecology (JSOG).

Journal of gynecologic oncology·2026
Same author

Advanced rectal cancer with multiorgan metastasis detected after single fetal death in twin pregnancy: a case report.

AME case reports·2026
Same author

In-utero cell transplantation for hypophosphatasia with gene-edited hESC-derived MSCs in a murine model.

Molecular therapy. Advances·2026

Related Experiment Video

Updated: Jul 4, 2025

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing
05:35

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing

Published on: September 15, 2023

1.5K

Intraperitoneal Carboplatin for Ovarian Cancer - A Phase 2/3 Trial.

Shoji Nagao1, Keiichi Fujiwara1, Kouji Yamamoto2

  • 1Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka City, Japan.

NEJM Evidence
|February 6, 2024
PubMed
Summary

Intraperitoneal carboplatin combined with dose-dense paclitaxel modestly improved progression-free survival in advanced ovarian cancer patients. This treatment approach showed benefits regardless of residual tumor size, without increasing non-catheter-related toxicities.

More Related Videos

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

10.9K
In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose
13:04

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose

Published on: October 14, 2015

13.1K

Related Experiment Videos

Last Updated: Jul 4, 2025

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing
05:35

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing

Published on: September 15, 2023

1.5K
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

10.9K
In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose
13:04

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose

Published on: October 14, 2015

13.1K

Area of Science:

  • Gynecologic Oncology
  • Clinical Pharmacology
  • Cancer Treatment

Background:

  • Intraperitoneal chemotherapy offers potential survival benefits for advanced epithelial ovarian cancer but lacks widespread clinical adoption.
  • The Intraperitoneal Therapy for Ovarian Cancer with Carboplatin (iPocc) trial investigated the efficacy and safety of this approach.

Purpose of the Study:

  • To evaluate the impact of intraperitoneal carboplatin combined with dose-dense intravenous paclitaxel on progression-free survival (PFS) in newly diagnosed advanced epithelial ovarian cancer.
  • To assess secondary endpoints including overall survival, tumor response, treatment completion, and adverse events.

Main Methods:

  • An open-label, international, randomized phase 2/3 clinical trial involving 655 women with newly diagnosed epithelial ovarian cancer.
  • Patients received intravenous paclitaxel plus either intravenous carboplatin (dd-TCiv) or intraperitoneal carboplatin (dd-TCip).
  • The primary endpoint was progression-free survival (PFS).

Main Results:

  • Median PFS was 23.5 months for the intraperitoneal carboplatin group (dd-TCip) versus 20.7 months for the intravenous carboplatin group (dd-TCiv), representing a statistically significant improvement (P=0.04).
  • The PFS benefit was consistent across various patient subgroups, including those with different baseline characteristics, stage, residual tumor size, age, and performance status.
  • Treatment completion rates were 59.9% for dd-TCip and 68.3% for dd-TCiv. Intraperitoneal catheter-related adverse events occurred in 10.1% of the dd-TCip group.

Conclusions:

  • First-line intraperitoneal carboplatin, when administered with dose-dense weekly paclitaxel, offers a modest prolongation of PFS in advanced epithelial ovarian cancer.
  • This benefit is observed irrespective of residual tumor size and does not increase non-catheter-related toxicities.
  • Intraperitoneal chemotherapy represents a viable treatment intensification strategy for this patient population.